See if suicidal behavior in kids during the Covid-19 period in the Auvergne-Rhone-Alpes region changed

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study analyzes aggregated data on pediatric suicidality during 2020–2022 across several hospitals in the Auvergne-Rhône-Alpes region. It includes age groups from 8 to under 18 and uses qualitative interviews to add context to the data. The approach combines data collection with patient interviews to explore experiences during the COVID-19 pandemic and related social restrictions. The aim is to understand patterns and potential factors related to the pandemic period. No experimental interventions are performed; data is observational and retrospective.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The population (subjects and controls) will be divided into age categories:

  * Pre-adolescents (≥ 8 years and \< 11 years)
  * Adolescents (≥ 11 years and \< 15 years)
  * Older adolescents (≥ 15 years and \< 18 years)

Subjects with suicidal behavior during the health crisis (Group 1):

* Age \> 8 years and \< 18 years during the period 2020 to 2022.
* Admitted to pediatric emergency departments or hospitalized in a care unit (CHU, general hospitals) in the AURA region during 2020, 2021, and/or 2022 for suicidal behavior (defined as suicidal ideation and/or suicide attempt and/or self-harm/self-poisoning with suicidal intent).

Subjects with suicidal behavior during the health crisis with qualitative interviews (Group 1b):

* Age \> 8 years and \< 18 years during the period 2020 to 2022.
* Admitted to pediatric emergency departments or hospitalized in a care unit (CHU, general hospitals) in the AURA region during 2020, 2021, and/or 2022 for suicidal behavior (defined as suicidal ideation and/or suicide attempt and/or self-harm/self-poisoning with suicidal intent).
* Randomly selected from the population of Group 1.
* For whom the parent(s) and/or the subject have signed informed consent.

Controls with suicidal behavior before the health crisis (Group 2):

* Age \> 8 years and \< 18 years during the period 2018 to 2019.
* Admitted to pediatric emergency departments or hospitalized in a care unit (CHU, general hospitals) in the AURA region during 2018 and/or 2019 for suicidal behavior (defined as suicidal ideation and/or suicide attempt and/or self-harm/self-poisoning with suicidal intent).

Exclusion Criteria:

\- Subjects with Suicidal Behavior during the Health Crisis with and without Qualitative Interviews (Group 1 and 1b):

• Admitted to pediatric emergency services or hospitalized in a healthcare facility (university hospital center, general hospital) in the AURA region for a psychiatric reason other than suicidal behavior during the period from 2020 to 2022.

Controls with Suicidal Behavior before the Health Crisis (Group 2):

* Admitted to pediatric emergency services or hospitalized in a healthcare facility (university hospital center, general hospital) in the AURA region for a psychiatric reason other than suicidal behavior during the period from 2018 to 2019.
* Intercurrent illness with a life expectancy of less than 24 hours.

For Group 1:

* Pregnant, postpartum, or breastfeeding women.
* Persons deprived of liberty by judicial or administrative decision.
* Adults subject to a legal protection measure (guardianship, curatorship).
* Persons not affiliated with a social security scheme or beneficiaries of a similar scheme.
* Persons who do not understand and do not speak French.

Where it's running

• Hospices Civils de Lyon - Hôpital Femme Mère Enfant- Service de pédopsychiatrie de l'enfant et de l'adolescent
  Bron, France Recruiting
• CHU de Clermont-Ferrand - Service de psychiatrie de l'enfant et de l'adolescent
  Clermont-Ferrand, France Not yet recruiting
• CHU de Grenoble - Service de psychiatrie de l'enfant et de l'adolescent
  Grenoble, France Not yet recruiting
• CHU de Saint-Etienne - Urgences psychiatriques
  Saint-Etienne, France Not yet recruiting

Study contacts

• Study coordinator: Elise MAMIMOUE, Dr
• Email: Elise.mamimoue@chu-lyon.fr
• Phone: 472129567

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.